Immunovant (IMVT) Q2 2027 earnings review
Immunovant's arthritis trial succeeded, but its skin lupus trial failed
Immunovant, a drug developer with no sales, passed a placebo test in rheumatoid arthritis but shortened its list of target diseases. More than nine in ten patients who stayed on the higher dose kept their improvement, against about three in four on placebo. The lower dose did not beat placebo. Trial spending fell, so the quarterly loss narrowed to $97 million.
| Patients keeping their arthritis improvement on the 600 mg dose | 92.5% 75.6% on placebo |
|---|---|
| Net loss | $97.2M $126.5M a year ago |
| Cash | $722.3M $797.8M three months earlier |
| Cash outlook | Unchanged lasts to a possible Graves' disease launch; excludes a second arthritis trial |
⚖️ Verdict: 🟢 Bullish
The story got better because the arthritis trial, the biggest near-term risk for this one-drug company, met its main goal. On the other side, the drug failed in skin lupus in September, and Immunovant said it will probably not pursue Sjögren's disease. Its cash plan also excludes the second arthritis trial under discussion.
The question now is what the US drug regulator will demand before it approves the drug in arthritis. If one more trial is enough, the cost stays limited; if it wants more, Immunovant must raise money sooner. A meeting planned before year-end will tell.
🐂 Bull Case
The Arthritis Trial Met Its Main Goal
IMVT-1402 is Immunovant's only drug, a weekly injection that lowers the antibodies behind autoimmune diseases. The biotech tested it in rheumatoid arthritis patients who had failed at least two kinds of advanced medicine.
Every patient first took the 600 mg dose for 16 weeks. Those who improved then continued for 12 more weeks on the same dose, on a half dose, or on placebo. The main measure was ACR20, an improvement of at least 20% in tender and swollen joints.
- Kept the improvement to week 28 on 600 mg: 92.5% of 40 patients
- Kept it on placebo: 75.6% of 41 patients
- Gap: 16.9 percentage points by our math, with a p-value of 0.0139
- Serious side effects in the second stage: none in any group
Immunovant calls the trial "potentially registrational", so the data could support a request for approval. A miss in this placebo stage would have left the arthritis programme without a controlled win.
What to watch: Immunovant's meeting with the US Food and Drug Administration, which the biotech plans before the end of 2026. Agreement on one further trial would confirm that this result counts toward approval.
Only the Higher Dose Beat Placebo
Immunovant's main claim for its drug IMVT-1402 is that it cuts harmful antibodies called IgG more deeply than rival drugs. Roivant chief executive Matt Gline, whose company controls Immunovant, told investors that "depth of IgG suppression really matters across FcRn indications". FcRn is the protein the drug blocks.
The arthritis trial fits. Patients on the 300 mg dose kept their improvement at a rate of 75.0%, no different from placebo. "300 mg was not enough to preserve the response," Gline said. But Immunovant published no IgG readings from this trial, so outsiders cannot yet check the link.
What to watch: IgG data from the arthritis trial. A bigger antibody drop on the 600 mg dose would support depth as the reason the drug worked.
Graves' Disease Trials Stay on Schedule
Graves' disease, a hormone-system autoimmune disorder, is the launch Immunovant's cash outlook points to. Two trials of its drug IMVT-1402 that could support approval are running, and results remain due in calendar 2027. A trial in myasthenia gravis, a neurological autoimmune disease, has the same target year.
Roivant chief executive Matt Gline, who leads Immunovant's parent company, said "enrollment has been strong" in Graves'. He expects to narrow the timing soon, and spending supports him. Costs for hormone-disease programmes rose 48% in the fiscal first half, to $65.3 million. They dipped in the latest quarter, which Immunovant tied to manufacturing timing.
What to watch: the date Immunovant sets for the first Graves' results. An early-2027 date would support Gline's statement that the biotech reached this disease first.
🐻 Bear Case
Supporting Measures Missed Statistical Significance
Roivant chief executive Matt Gline spoke for Immunovant's parent company on the results call. He said "these placebo patients really worsened, whereas the drug patients were able to preserve their response through week 28". The remark covered CDAI and SDAI, two scores doctors use to track arthritis.
- CDAI change: -0.3 on the 600 mg dose of IMVT-1402 against +3.1 on placebo, p-value 0.1096
- SDAI change: +0.1 against +3.5, p-value 0.1299
Neither gap passes the usual 0.05 test, so chance could explain each one. Placebo patients also held up: three in four kept their improvement after the drug stopped.
What to watch: the next trial's design. Gline expects "a straightforward RCT", which compares drug and placebo across all patients from the first day.
Two Diseases Dropped Out of the Plan
Immunovant has one drug, IMVT-1402, so its prospects depend on how many diseases that injection can treat. Last quarter the biotech said trials in all six planned diseases were on track. Four remain.
A 57-patient trial in skin lupus missed its main goal in September, and Immunovant stopped that programme. In Sjögren's disease, another autoimmune condition, the biotech now thinks it "unlikely that we will advance IMVT-1402 further in SjD" after the current trial.
Roivant chief executive Matt Gline tied the Sjögren's decision to rivals' results in that disease. So this class of drug does not work everywhere antibodies play a part.
What to watch: any new disease Immunovant adds. A list that stays at four makes the 2027 Graves' disease and myasthenia gravis results decide most of the outcome.
The Cash Plan Leaves Out the Next Trial
Immunovant has no revenue, so its cash sets how long it can run trials. The biotech says the money lasts "to the potential commercial launch of IMVT-1402 in GD", meaning its only drug in Graves' disease. That statement carries no date.
- Cash at September 30: $722.3 million, down $75.5 million in three months
- Research and development cost: $85.0 million, against $114.2 million a year ago
Immunovant said the research saving came partly from "the timing of contract manufacturing costs", and timing only moves a cost between quarters. The filing also says any wider late-stage plan, such as a second arthritis trial, is "not reflected in our current operating plan". So the arthritis success adds costs that the cash outlook does not count.
By our math, the balance covers about eight quarters at the six-month pace, before any new trial. Research spending had climbed 41% in the previous quarter, so one calm quarter does not set the pace.
What to watch: the updated cash outlook Immunovant expects to give once its plans are final. A share sale alongside it would show the current balance cannot pay for the arthritis programme.
Risks this quarter didn't answer
Three standing risks drew no evidence that settles them in the release, the filing or the call. Each still awaits the event named below.
- Rival drugs in Graves' disease and myasthenia gravis: no new facts on competitors' timing. The 2027 results for Immunovant's drug IMVT-1402 will show the gap.
- HanAll, which licensed the drug: talks on the dropped drug batoclimab continue, and the filing warns HanAll "may disagree". A settlement or an arbitration claim would move it.
- Roivant, the parent company: another shareholder sued in September over a January 2025 share sale to Roivant. The defendants reject the claims.
What to watch: the next quarterly filing, for any change in the HanAll talks or the lawsuit. A HanAll dispute would matter most, because that licence also covers the only drug.
👓 Other Themes
Regulator Talks on Arthritis Are Not Finished
Roivant chief executive Matt Gline leads Immunovant's parent. He said the group released the arthritis data before finishing talks with the regulator "because we hit a p-value unexpectedly". Gline does not yet know whether one more trial of IMVT-1402, the only drug, will be enough for approval. Immunovant plans to meet the Food and Drug Administration by the end of 2026.
Lower Rates Partly Offset Higher Cash Balances
Immunovant keeps $697.0 million of its cash in money market funds that hold US government securities. Interest income rose to $6.9 million from $5.6 million a year ago because balances were higher, the filing said. Lower average rates partly offset that. The filing also lists tariffs, inflation and conflicts in the Middle East as possible risks to trial timelines.
💲 Other KPIs
The share count grew 19% from a year ago because Immunovant sold $550 million of stock last December. That growth rate has slowed for three quarters as the sale ages. Option exercises added 2.8 million shares since March. Extra shares spread the loss thinly, so loss per share shrank faster than the loss itself.
Overhead rose 9% from a year ago, the first increase after four quarters of declines. Immunovant said the reason was "higher investments in pre-commercial activities", meaning early preparation to sell a drug. Excluding stock awards, the figure was $12.4 million against $11.9 million.
Accrued expenses, costs Immunovant has booked but not yet paid, stood close to March's $96.9 million. Of the total, $42.5 million relates to batoclimab, the older drug the biotech stopped in April. That payment has not left the cash balance yet. Accrued research bills rose to $45.0 million from $33.9 million.
The quarterly loss narrowed 23% from a year ago, to $0.47 a share. Over six months the picture differs: the loss widened 1%, to $250.5 million, because trial and manufacturing costs were heavy in the first quarter. Excluding stock awards, the quarterly loss was $84.0 million.
🔮 Guidance
Unchanged. Immunovant still says its $722.3 million lasts until a possible Graves' disease launch, with no date attached. By our math, the balance covers about 9.6 quarters at this quarter's pace of decline and 6.9 at the previous quarter's. The plan excludes any added late-stage trials, and the filing says a new cash outlook will follow once those plans are final.
Unchanged. Results from two Graves' disease trials and one myasthenia gravis trial remain due in calendar 2027. Roivant chief executive Matt Gline said he expects to narrow the timing relatively soon. This target has now held for five straight quarterly reports.
Unchanged. Immunovant still expects 2028 results from its trial in CIDP, a neurological autoimmune disease. The trial runs for 24 weeks against placebo and could support a request for approval. It is now the last of the four remaining programmes on the calendar.
Unchanged. Immunovant delivered the trial update inside the half-year it named and now plans to meet the US regulator by year-end. Gline said the group will report the agreed trial plan later this year or early next year. He expects an ordinary placebo-controlled design, not another withdrawal study.
Cut. Immunovant no longer expects to take the drug further in Sjögren's disease once the current, fully enrolled trial ends. Three months ago it listed 2028 results from a trial that could support approval. Gline said rivals' results in this disease drove the change, and that a surprise in the trial data could reopen it.
❓ Key Questions
What will the second arthritis trial cost?
The filing says wider late-stage plans sit outside the current operating plan. Readers cannot judge how long $722.3 million lasts until Immunovant gives the cost and says whether new shares, Roivant or a partner will pay.
When could a Graves' disease drug reach the market?
The cash outlook runs to a possible Graves' disease launch but names no date. Trial results arrive in 2027, and a filing and review must follow. A date would let readers test the cash statement.
How far did IgG fall on each dose?
Gline credits deeper antibody reduction for the 600 mg result, but Immunovant kept IgG data from this trial private for competitive reasons. Without it, nobody outside can confirm why 300 mg did not work.
How does Immunovant count 85,000 arthritis patients?
Gline put the US group at about 85,000 patients. Figures the company gave in May point to about 123,000 by our math. The difference cuts the opportunity by roughly a third.
What does HanAll want for the dropped drug?
Immunovant is discussing the return of batoclimab rights to HanAll, which licensed both drugs to it. The same contract covers IMVT-1402 and up to $420.0 million of future milestone payments. Readers need to know whether a dispute could touch the main drug.